Introducing Cognite AI, the Generative AI Accelerator for Industrial Data and Value Realization
Cognite, a globally recognized leader in industrial software, today announced the launch of Cognite AI, the Generative AI Accelerator for Industrial Data and Value Realization. Cognite AI, a comprehensive suite of Generative AI capabilities within Cognite’s core Industrial DataOps platform, Cognite Data Fusion®, adds to the company’s innovative industrial-specific offering around energy, manufacturing, and power and renewables, and is fully open to all partners to create tailored industrial solutions. Cognite Data Fusion® with Cognite AI improves operations by rapidly accelerating cloud adoption and increasing the efficiency of industrial workflows by 10x.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230613143597/en/
Cognite AI, the Generative AI Accelerator for Industrial Data and Value Realization. (Graphic: Business Wire)
In industrial organizations, significant domain-specific context is required before Generative AI can be applied to critical decision-making across low risk tolerance domains in production, maintenance, and reliability. Cognite AI solves this industrial data and AI problem by delivering simple access to complex industrial data and building Generative AI into every aspect of the product experience, enabling stakeholders in both IT and Operations to generate valuable, cross-data-source insights.
“Industrial data is a critical part of making informed decisions on business operations, yet complex and labor intensive to reconcile into actionable insights,” said Judson Althoff, executive vice president and chief commercial officer, Microsoft. “Cognite AI addresses this need by building upon the power of the Microsoft Cloud and its AI capabilities to deliver rich, contextualized data and generative AI analytics services to help energy, manufacturing, and power and renewables customers accelerate efficiency and value realization of their industrial workflows.”
“Celanese is building the Digital Plant of the Future and we rely on Cognite Data Fusion on Microsoft Azure to put the right data into the hands of our experts so they can spend less time identifying problems and more time finding solutions,” said Ibrahim Al-Syed, Director of Digital Manufacturing at Celanese. “Generative AI is a powerful tool that will be key to enabling our people. With Cognite AI as part of our digital strategy, we can improve work experiences by unifying people, data, processes, and systems with a common platform.”
“Cognite AI accelerates the application of modern software technology in industrial digitalization. It informs the industrial user, empowers the industrial operator and enables industrial facilities to be efficient and sustainable,” said Girish Rishi, Cognite CEO. “With Cognite AI, we have developed an innovative architecture that eliminates hallucinations, mitigates data leakage, and enables trust and access control. This is how we make AI work for industry.”
Cognite Data Fusion® delivers revolutionary cross-domain collaboration to drive operational excellence with capabilities that include:
- Cognite AI: An innovative architecture that unifies Generative AI (LLMs such as GPT 3.5/4 and PaLM) with Cognite’s specific Data Modeling and Retrieval-Augmented Generation (RAG) capabilities. Cognite AI uniquely augments the ability of generic-purpose LLMs to retrieve data from customers’ private sources to generate more purposeful, accurate, and sophisticated outputs based on customers’ own private industrial data, within the customers’ secure and protected SaaS tenant. Cognite AI provides business end-users a way to create low code applications using natural language.
- Industrial DataOps: Get AI-enhanced data onboarding from all OT, IT, engineering, and robotics data sources, complete with lineage, quality assurance, and governance. These market leading Industrial DataOps capabilities are a requirement for a robust data foundation to scale asset-to-asset and site-to-site in hours and weeks, not months.
- Data Modeling: Built-in AI contextualization to automatically map data relationships, creating a living industrial knowledge graph, and building the foundation for real-time digital twins that are automatically enriched with live data and event streams. Capture field worker notes and observations all in context, all instantly sharable.
- Industrial Canvas: Get all OT, IT, engineering, robotics data (time series, events, P&IDs, documents, work orders, asset hierarchies, images, simulation, 3D, and more) in a single, collaborative workspace with native AI Copilot functionality to answer operational questions, compile and develop no-code applications, and analyze complex scenarios up to 90% faster than before.
- APM Intelligence App Suite: Three ready-to-use cross data-source applications for digital-first age business workflows across reliability, operations, and maintenance, and accelerate value realization from existing APM investments without complex and costly rearchitecting and change management programs.
Request a demo and learn more about how Cognite Data Fusion® with Cognite AI empowers operations, digital teams, application developers, and more with true, at scale digital transformation: Cognite.ai.
About Cognite
Cognite is a globally recognized leader in industrial software with a clear vision: to rapidly empower industrial companies with accessible, trustworthy, and contextualized data and drive the full-scale digital transformation of asset-heavy industries. With its market-leading Industrial DataOps platform, Cognite Data Fusion®, and a comprehensive suite of Industrial Generative AI capabilities, Cognite AI, Cognite makes it easy for decision-makers to access and understand complex industrial data. Cognite Data Fusion® is a user-friendly, secure, and scalable platform that enables industrial data and domain users to collaborate quickly and safely to develop, deploy, and scale Industrial Generative AI solutions that deliver both profitability and sustainability. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230613143597/en/
Contact information
Michelle Holford
Vice President, Global PR Cognite
Michelle.Holford@cognite.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom